Coronary Artery Disease Clinical Trials & Research Studies Near You (Updated 6/24)

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120

Recruiting

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups. Read Less

Gender:

Female

Ages:

18 years and above

Trial Updated:

12/19/2023

Locations: Cedars-Sinai Medical Center, Los Angeles, California +102 locations

Cedars-Sinai Medical Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Yale University Hospital, New Haven, Connecticut

University of Chicago, Chicago, Illinois

Johns Hopkins University, Baltimore, Maryland

Baystate Health, Springfield, Massachusetts

Washington University in St. Louis, Saint Louis, Missouri

Nebraska Heart Hospital, Lincoln, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Englewood Health, Englewood, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

The Valley Hospital, Ridgewood, New Jersey

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

Weill Cornell Medicine, New York, New York

Icahn School of Medicine, Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

Lenox Hill Hospital, New York, New York

New York Presbyterian Queens, Queens, New York

Duke University, Durham, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University, Columbus, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Baylor Scott & White Research Institute, Dallas, Texas

University of Utah, Salt Lake City, Utah

The University of Melbourne, Melbourne, Not set

Medical University of Graz, Graz, Not set

Innsbruck Medical University, Innsbruck, Not set

Kepler University Hospital, Linz, Not set

Medical University of Vienna, Vienna, Not set

Krankenhaus Nord Vienna North Hospital, Vienna, Not set

Institute of Cardiology Porto Alegre, Porto Alegre, Not set

Heart Institute University of São Paulo, São Paulo, Not set

Instituto Dante Pazzanese de Cardiologia, Vila Mariana, Not set

St. Boniface General Hospital, Winnipeg, Manitoba

Horizon Health Network - Saint John Regional Hospital, Saint John, New Brunswick

Hamilton General Hospital, Hamilton, Ontario

London Health Sciences, London, Ontario

University of Ottawa Heart Institute, Ottawa, Ontario

Health Sciences North, Sudbury, Ontario

Sunnybrook Health Sciences, Toronto, Ontario

Toronto General Hospital, Toronto, Ontario

Montreal Heart Institute, Montréal, Quebec

University Hospital of Montreal, Montréal, Quebec

Royal Victoria Hospital, Montréal, Quebec

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Ste Foy, Quebec

Hopital Sacre-Coeur, Montréal, Not set

Fraser Clinical Trials, New Westminster, Not set

Fuwai Hospital China, Beijing, Beijing

Jilin Heart Hospital China, Changchun, Jilin

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

Teda Hospital Tianjin China, Tianjin, Tianjin

University Hospital Dubrava, Zagreb, Not set

University Hradec Králové, Hradec Králové, Not set

General University Hospital, Prague, Nové Město, Not set

Universitäts-Herzzentrum Bad Krozingen Freiburg, Bad Krozingen, Baden-Wuerttemberg

HDZ NRW Bad Oeynhausen Germany, Bad Oeynhausen, Not set

Deutsches Herzzentrum der Charite, Berlin, Not set

Essen University, Duisburg, Not set

Duisburg Heart Center, Duisburg, Not set

Dusseldorf University, Düsseldorf, Not set

University Hospital Erlangen, Erlangen, Not set

Frankfurt University, Frankfurt, Not set

University Hospital of Giessen and Marburg, Gießen, Not set

University Medical Center of Göttingen, Göttingen, Not set

Jena University Hospital, Jena, Not set

Heart Center Herzzentrum, Leipzig, Leipzig, Not set

Robert-Bosch-Hospital Stuttgart Germany, Stuttgart, Not set

Krankenhaus der Barmherzigen Brüder Trier, Trier, Not set

G Kuppuswamy Naidu Memorial Hospital (GKNM), Coimbatore, Tamil Nadu

Star Hospitals - Hyderabad, India, Hyderabad, Telangana

Rambam Health Care Campus, Haifa, Not set

Anthea Hospital, Bari, Not set

Fondazione Poliambulanza, Brescia, Not set

Maria Cecilia Hospital GVM, Cotignola, Not set

European Hospital, Roma, Not set

Universita' Cattolica del Sacro Cuore, Roma, Not set

Ospedale Le Molinette, Torino, Torino, Not set

Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo

Saitama Medical University Japan, Saitama, Not set

Seoul National University Hospital, Seoul, Not set

Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seúl, Not set

Maastricht University Medical Centre, Maastricht, Not set

Acibadem-Sistina Hospital, Skopje, Not set

Medical University of Silesia, Katowice, Not set

Zbigniew Religa Lower Silesian Heart Disease Centre, Zabrze, Not set

University Hospital Coimbra, Coimbra, Not set

Centro Hospitalar Lisboa Ocidental, Lisboa, Not set

Centro Hospitalar e Universitário Sao João, Porto, Not set

National Research Medical Center of the Russian Academy of Sciences - Tomsk, Russia, Tomsk, Not set

Dedinje Cardiovascular Institute, Belgrade, Not set

National University of Singapore, Singapore, Not set

Hospital Universitario del Vinalopo, Elx, Alicante

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Clinico de San Carlos, Madrid, Not set

NavarraBiomed, Pamplona, Not set

Sahlgrenska University Hospital, Gothenburg, Not set

National Taiwan University Hospital, Zhongzheng, Taipei

Hull University Hospitals, Hull, Not set

University Hospitals of Leicester, Leicester, Not set

St George's University Hospitals, London, Not set

Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Register for Updates

Learn More ›

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240

Recruiting

Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while... Read More

Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD. Read Less

Gender:

All

Ages:

All

Trial Updated:

12/13/2023

Locations: Huntsville Heart Center, Huntsville, Alabama +71 locations

Huntsville Heart Center, Huntsville, Alabama

Arizona Cardiovascular Research, Phoenix, Arizona

Veteran Affairs Palo Alto Health Care System, Palo Alto, California

Loma Linda University, Redlands, California

Santa Barbara Cottage Hospital, Santa Barbara, California

Torrance Memorial Medical Center, Torrance, California

JFK Medical Center, Atlantis, Florida

Baptist Health Jacksonville, Jacksonville, Florida

Miami Cardiac and Vascular/Baptist Hospital, Miami, Florida

Piedmont, Atlanta, Georgia

Northeast Georgia Health System, Gainesville, Georgia

St. Alphonsus Regional Medical Center, Boise, Idaho

Ascension Alexian Brothers, Chicago, Illinois

Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana

Parkview Research Center, Fort Wayne, Indiana

University of Kansas Medical Center, Kansas City, Kansas

Midwest Heart and Vascular, Overland Park, Kansas

Cardiovascular Research Institute of Kansas, Wichita, Kansas

Tufts Medical, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Sparrow Clinical Research Institute, Lansing, Michigan

William Beaumont Hospital, Royal Oak, Michigan

Ascension St. Mary's, Saginaw, Michigan

St. Joseph Mercy Health System, Ypsilanti, Michigan

University of Minnesota Medical Center, Minneapolis, Minnesota

CentraCare Heart and Vascular Center, Saint Cloud, Minnesota

Boone Hospital, Columbia, Missouri

St. Louis University, Saint Louis, Missouri

Missouri Baptist, Saint Louis, Missouri

Bryan Heart, Lincoln, Nebraska

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Our Lady of Lourdes, Camden, New Jersey

Valley Hospital, Ridgewood, New Jersey

Montefiore Medical Center, Bronx, New York

University at Buffalo, Buffalo, New York

NYU Langone Hospital - Long Island, Mineola, New York

Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

St. Joseph's Hospital, Syracuse, New York

Novant Health Heart and Vascular Institute, Charlotte, North Carolina

Summa Health System, Akron, Ohio

Mount Carmel, Columbus, Ohio

Oklahoma Heart, Oklahoma City, Oklahoma

Kaiser Permanente Northwest, Clackamas, Oregon

Rhode Island Hospital, Providence, Rhode Island

Methodist Le Bonheur Healthcare, Germantown, Tennessee

Ballad Health CVA Heart Institute, Kingsport, Tennessee

Parkwest Medical Center, Knoxville, Tennessee

Cardiovascular Surgery Clinic/Baptist Memorial, Memphis, Tennessee

HCA Houston Healthcare Medical Center, Houston, Texas

Baylor Scott & White Plano, Plano, Texas

Baylor Scott & White Round Rock, Round Rock, Texas

University of Vermont Medical Center, Burlington, Vermont

Bellin Health System, Green Bay, Wisconsin

Ascension Columbia St. Mary's, Milwaukee, Wisconsin

University of Alberta, Mazankowski Heart Institute, Edmonton, Alberta

Royal Columbian Hospital, New Westminster, British Columbia

Vancouver General Hospital, Vancouver, British Columbia

Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire (CCI-CIC), Vancouver, British Columbia

St. Paul's Hospital, Vancouver, British Columbia

Saint Boniface, Winnipeg, Manitoba

New Brunswick Heart, Saint John, New Brunswick

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia

Hamilton Health Sciences, Hamilton, Ontario

Ottawa Heart, Ottawa, Ontario

Sunnybrook Hospital, Toronto, Ontario

St. Michael's Hospital, Toronto, Ontario

Montréal Heart, Montréal, Quebec

Centre Hospitalier de l'Université de Montréal, Montréal, Quebec

Sacré-Coeur, Montréal, Quebec

CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec

Prairie Vascular, Regina, Saskatchewan

Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis

Register for Updates

Learn More ›

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307

Recruiting

Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant

Gender:

Male

Ages:

Between 18 years and 99 years

Trial Updated:

12/12/2023

Locations: Indiana University, Indianapolis, Indiana

Conditions: Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications

Register for Updates

Learn More ›

FAME II-10-year Follow-Up

NCT06159231

Recruiting

The FAME-II trial was a prospective, multicenter, multinational, multi-continental, randomized clinical trial with an 'all comers' design. The overall purpose of the FAME-II trial was to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease and in whom both PCI and medical treatment can be considered on the basis of the presently existing scientific evidence. FAME-II w... Read More

Gender:

All

Ages:

21 years and above

Trial Updated:

12/05/2023

Locations: Stanford University Medical Center, Stanford, California +24 locations

Stanford University Medical Center, Stanford, California

Emory University Hospital, Atlanta, Georgia

Atlanta VA Medical Center, Decatur, Georgia

Northern Light Eastern Maine Medical Center, Bangor, Maine

Cardiovascular Center Aalst, Aalst, Not set

CHUM (Centre hospitalier de l'Université de Montréal), Montréal, Quebec

Hôpital du Sacré-Cœur-de-Montréal, Montréal, Quebec

Masaryk University - Dept. of Internal Cardiology Medicine, Brno, Moravia

Nemocnice Na Homolce, Praha, Not set

Rigshospitalet, Copenhagen, Not set

Hopital Cardiovasculaire et Pneumologique Louis Pradel, Bron, Lyon

Universität Leipzig Herzzentrum, Leipzig, Saxony

München Klinikum Innenstadt, München, Not set

Städtische Krankenhaus München-Bogenhausen, München, Not set

Gottsegen Hungarian Institute of Cardiology, Budapest, Not set

Azienda Ospedaliera Universitaria S. Anna (Ferrara), Cona, Ferrara

Catharina Ziekenhuis, Eindhoven, Noord-Brabant

Clinical Hospital Center Kragujevac, Kragujevac, Šumadija

Sodersjukhuset, Stockholm, Not set

Universitestssjukhuset i Örebro, Örebro, Not set

King's College Hospital, London, Camberwell

Southampton University Hospital - Wessex Cardiac Unit, Southampton, Hampshire

Edinburgh Heart Centre, Edinburgh, Scotland

Royal Victoria Hospital, Belfast, Ulster

Golden Jubilee National Hospital, Clydebank, Not set

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

A Sugar-Sweetened Beverage Reduction Intervention for Native American Men

NCT06029517

Recruiting

This clinical trial develops and tests a culturally-appropriate educational program (Indigenous SIPin) for reducing sugar-sweetened beverage consumption in men affiliated with Native American athletics communities. Sugary drinks are drinks like pop, soda, and juice. Increased sugar consumption may lead to an increased risk of chronic diseases, including obesity, diabetes, some types of obesity-related cancers, coronary heart disease, hypertension, and dental decay. A culturally sensitive program... Read More

Gender:

Male

Ages:

18 years and above

Trial Updated:

12/04/2023

Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York

Conditions: Cardiovascular Disorder, Coronary Artery Disease, Diabetes Mellitus, Obesity-Related Malignant Neoplasm

Register for Updates

Learn More ›

Digital Monitoring for Patients Post Coronary Interventions to Reduce Risk for Recurrent Adverse Cardiovascular Events

NCT06114615

Recruiting

The study aims to support patients immediately after percutaneous coronary intervention (PCI) by implementing a telemonitoring program. Eligible patients have coronary heart disease and undergo PCI. The intervention group receives remote monitoring and text-based follow-up, with established health goals and education on using the telemonitoring application, along with necessary devices. The control group gets standard care. Outcomes measured include blood pressure, LDL levels, patient satisfacti... Read More

Gender:

All

Ages:

All

Trial Updated:

11/27/2023

Locations: University of California, Davis Medical Center Division of Cardiovascular Medicine, Sacramento, California

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women

NCT05169840

Recruiting

The investigators propose to genotype males and females at age 40 years and older, who are asymptomatic and without known heart disease (N=2000). DNA from a blood sample will be genotyped for millions of genetic risk variants for CAD by Baylor College of Medicine Human Genome Sequencing Center Clinical Laboratory (HGSC-CL) in a CLIA-approved laboratory. The overall objective after 2 years is to determine if genetic screening for risk of CAD in asymptomatic men and women has the discriminatory p... Read More

Gender:

All

Ages:

Between 40 years and 60 years

Trial Updated:

11/22/2023

Locations: Chandler Regional Medical Center, Chandler, Arizona +2 locations

Conditions: Coronary Artery Disease, Genetic Predisposition to Disease

Register for Updates

Learn More ›

Precision PCI Registry

NCT06143709

Recruiting

The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to include on a genetic testing panel, and how to change antiplatelet therapy based on genotype results and other patient-specific factors is needed to optimize the impact of genotype-guided antiplatelet therapy on patient outcomes. The Precision PCI registry is a collaboration between the University of... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

11/16/2023

Locations: University of Florida, Gainesville, Florida

Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention

Register for Updates

Learn More ›

The Precision CAD Trial

NCT04755413

Recruiting

People with Coronary Artery Disease (CAD) have narrow or blocked arteries that supply blood to the heart. Reduced blood flow to the heart muscle from CAD can cause chest pain or aching, especially with exercise or activity. CAD can lead to weakening of the heart muscle or heart failure, and a higher risk of heart attack or death. Certain proteins in the blood, known as biomarkers, can be found in people with CAD. Higher levels of these biomarkers are associated with a greater risk of complicatio... Read More

Gender:

All

Ages:

Between 21 years and 90 years

Trial Updated:

10/25/2023

Locations: Emory Johns Creek Hospiatl, Atlanta, Georgia +4 locations

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Is Our Microbiome a Predictor of Cardiac Risk

NCT02013284

Recruiting

The purpose of this study is to determine a relationship between a person's flora/bacteria in their gut (the intestinal microbiome) and their risk of cardiovascular disease. Investigators will look at inflammatory markers in the blood and also look at the genome of the bacteria in the gut.

Gender:

All

Ages:

18 years and above

Trial Updated:

10/24/2023

Locations: Mayo Clinic, Rochester, Minnesota

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity

NCT04717050

Recruiting

This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.

Gender:

Female

Ages:

18 years and above

Trial Updated:

09/25/2023

Locations: Dana Farber Cancer Institute, Boston, Massachusetts

Conditions: Breast Cancer, Coronary Artery Disease, Stroke, Type2 Diabetes

Register for Updates

Learn More ›

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03404180

Recruiting

Surgery performed with nerve blocks and sedation may be safer and provide better pain control compared to general anesthesia and opioid therapy in high-risk patient populations such as elderly and troubled with peripheral vascular disease, diabetes, hypertension, coronary artery disease, and chronic obstructive pulmonary disease (COPD).

Gender:

All

Ages:

18 years and above

Trial Updated:

09/14/2023

Locations: University of Florida, Gainesville, Florida

Conditions: Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive

Register for Updates

Learn More ›

Coronary Artery Disease Clinical Trials

Match to Clinical Trials